{"entity":{"id":"fs-207","kind":"drug","name":"FS-207","aka":[],"tldr":"FS-207 is an experimental oral small molecule from Fushi Biotechnology, in phase 1 trials for MSI-high advanced solid tumours.","summary":"FS-207 is an oral small molecule (tablet) from Fushi Biotechnology. Targets the WRN helicase; developed for solid tumours with high microsatellite instability (MSI-H). Its furthest stage is phase 1, for MSI-high advanced solid tumours. ClinicalTrials.gov registers it in one study linked below. NMPA implied clinical trial approval April 2026 (company news); phase 1a/1b NCT07593144 not yet recruiting. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Fushi Biotechnology: foresightbiopharm.com","url":"https://www.foresightbiopharm.com/en/pipeline.html"},{"label":"Fushi Biotechnology: foresightbiopharm.com","url":"https://www.foresightbiopharm.com/"},{"label":"Fushi Biotechnology: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT07593144"},{"label":"ClinicalTrials.gov: trials of FS-207","url":"https://clinicaltrials.gov/search?intr=FS-207"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["wrn"],"drugs":[],"companies":["fushi-biotechnology"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07593144"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"FS-207","modality":"Oral small molecule (tablet)","mechanism":"Targets the WRN helicase; developed for solid tumours with high microsatellite instability (MSI-H).","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/fs-207/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"wrn","kind":"target","name":"WRN helicase (MSI-high cancers)","route":"/targets/wrn/"}],"company":[{"id":"fushi-biotechnology","kind":"company","name":"Fushi Biotechnology","route":"/companies/fushi-biotechnology/"}],"trial":[{"id":"nct07593144","kind":"trial","name":"A Single-Arm, Open-Label Phase Ia/Ib Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of FS-207 in Patients With Advanced Solid Tumors With High Microsatellite Instability (MSI-H)","route":"/trials/nct07593144/"}]}}